CLAIMS

1. ~~A~~ Use of a composition comprising ~~of~~ a cell population enriched for STRO-1^{bright} multipotential cells or progeny thereof ~~for~~ in the manufacture of a medicament for treating or preventing a disease in a subject arising from degradation and/or inflammation of cartilage by preserving or generating cartilage that is rich in proteoglycans~~connective tissue~~.

~~2. The composition of claim 1, wherein the connective tissue is rich in proteoglycans.~~

~~3. The composition of claim 1 or claim 2, wherein the connective tissue is cartilage.~~

~~4. The composition of claim 3, wherein the disease results in one or more defects in the cartilage.~~

~~5~~2. The ~~composition~~use of claim 4, wherein the ~~composition~~ medicament is not ~~directly~~ for direct ~~administered~~ administration into ~~a~~ the degraded and/or inflamed cartilage ~~defect~~.

~~6~~3. The ~~composition~~ use of any one of claims 1 to ~~5~~2, wherein the ~~composition~~ medicament is in a form suitable for administration to a joint space.

~~7~~4. The ~~composition~~use of claim ~~6~~3, wherein the joint space is in a knee joint, hip joint, ankle joint, shoulder joint, elbow joint, wrist joint, hand or finger joint or a joint of the foot, or an intervertebral disc joint.

~~8~~5. The ~~composition~~use of claim ~~6~~ 3 or claim ~~7~~4, wherein the ~~MPCs and/or progeny cells and/or soluble factors are~~medicament is suitable for administration ~~administered~~ by intra-articular injection.

~~9. The composition of any one of claims 1 to 8, wherein the administration of composition results in preservation or generation of cartilage that is rich in proteoglycans.~~

~~10~~6. The ~~composition~~ use of claim ~~9~~1, wherein the cartilage that is rich in proteoglycan is hyaline cartilage.

~~11~~7. The ~~composition~~ use of any one of claims 1 to ~~10~~ 6 wherein the disease is tendonitis, back pain, rotary cuff tendon degradation, Carpal tunnel syndrome, DeQuervain's syndrome, degenerative cervical and/or lumbar discs, intersection

syndrome, reflex sympathetic dystrophy syndrome (RSDS), stenosing tenosynovitis, epicondylitis, tenosynovitis, thoracic outlet syndrome, ulnar nerve entrapment, radial tunnel syndrome, repetitive strain injury (RSI), osteoarthritis, rheumatoid arthritis, psoriatic arthritis, seronegative arthritis, arthritis associated with inflammatory bowel disease or ankylosing spondylitis and degenerate invertebral disc disorders.

~~12~~8. The ~~composition~~ use of any one of claims 1 to ~~11~~7, wherein the medicament ~~which~~ further comprises ~~administering~~ a chondroprotective agent.

~~13. A composition comprising;~~

~~i) a cell population enriched for STRO-1^{bright} multipotential cells or progeny thereof and/or progeny cells thereof, and~~

~~ii) a chondroprotective agent.~~

~~14~~9. The ~~composition~~ use of ~~any one of claims~~claim ~~1-12~~ 8~~or 13~~, wherein the chondroprotective agent is hyaluronic acid~~cell population is an allogenic cell population~~.

~~15~~10. The ~~composition of any one of claims 1-12 or 14~~use of any one of claims 1-9, wherein the cell population is an allogenic cell population~~chondroprotective agent is hyaluronic acid~~.